Riskpilot← Back to searchSign inGet full accessNykode Therapeutics Denmark A/S
A/SActiveCVR 42038660Gammel Lundtoftevej 1EBusiness and other management consultancy activities · NACE 7020Est. 202113 employees
Revenue 2024
DKK 63,6M
+20% vs 2023
EBITDA margin
3.0%
-62% vs 2023
Equity ratio
27.0%
Financial strength
Net profit 2024
DKK 157K
-94% vs 2023
| Revenue | DKK 63,6M | +20% |
| EBITDA | DKK 1,9M | -62% |
| Net profit | DKK 157K | -94% |
| Total assets | DKK 20,4M | +0% |
| Equity | DKK 5,5M | +3% |
| Employees | 13 | — |
Legal name
Nykode Therapeutics Denmark A/S
CVR number
42038660
Legal form
Aktieselskab
NACE code
7020 · Business and other management consultancy activities
Founded
8. januar 2021
Share capital
DKK 400.000
Employees
13 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er at levere ledelsesmæssige, administrative og specialiserede tjenester inden for den biofarmaceutiske industri samt udøve anden virksomhed, der står i forbindelse hermed.
Address
Gammel Lundtoftevej 1E
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 10.591 | 38.639 | 52.928 | 63.553 |
| Staff expenses | -9.526 | -34.982 | -47.887 | -61.656 |
| EBITDA | 1.064 | 3.657 | 5.041 | 1.897 |
| Depreciation & amort. | -302 | -1.044 | -1.208 | -1.470 |
| EBIT | 763 | 2.613 | 3.833 | 426 |
| Net financials | -16 | -174 | -634 | -49 |
| Profit before tax | 747 | 2.438 | 3.199 | 377 |
| Tax | 169 | 543 | 714 | 220 |
| Net profit | 578 | 1.895 | 2.485 | 157 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 10.954 | 14.830 | 20.504 | 20.422 |
| Equity | 978 | 2.874 | 5.358 | 5.515 |
| Long-term debt | 0 | 6.377 | 4.356 | 3.102 |
| Short-term debt | 9.976 | 5.565 | 10.752 | 7.621 |
| Total debt | 9.976 | 11.941 | 15.108 | 10.722 |
EBITDA margin
3.0%
This company
15.8%
Market median
-81% vs market
20212024
Equity ratio
27.0%
This company
38.2%
Market median
-29% vs market
20212024
Return on equity
2.8%
This company
18.4%
Market median
-85% vs market
20212024
Net profit margin
0.2%
This company
8.1%
Market median
-98% vs market
20212024
Asset turnover
3.11×
This company
1.12×
Market median
+178% vs market
20212024
Debt / equity
2.70×
This company
0.62×
Market median
-335% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-08 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MT Management | Management | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (4) | ||
| Board of Directors | 2021 – 2022 | |
| Chairman | 2022 – 2022 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nykode Therapeutics Denmark A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Thyrring Engsig | Management | 0 companies |
| Louise Stubbe | Chairman | 0 companies |
| Harald Gurvin | Board of Directors | 0 companies |
| Katrine Hovgaard Husum | Board of Directors | 0 companies |
| Alf Gunnar Martin Nicklasson | Chairman | 0 companies |
| Anders Tuv | Chairman | 0 companies |
| Lars Dencker Nielsen | Board of Directors | 0 companies |